KMDA
HOLD / NEUTRALTrendComposite
44.20
Technical
46.20
Fundamental
41.80
Rank
—
Price
7.58
Hurst
0.63
As of
Aug 17, 2026
Daily
Kamada Ltd.
HealthcareDrug Manufacturers - Specialty & GenericKamada Ltd. manufactures plasma-derived protein therapeutics used for post-exposure and post-transplant prophylaxis, immune disorders, and hemostatic conditions, with products including rabies immunoglobulin, cytomegalovirus prophylaxis, varicella treatment, and clotting factor replacements. The company also distributes a range of biopharmaceutical medications in Israel covering respiratory diseases, allergies, rheumatologic conditions, infectious diseases, and oncology. Based in Rehovot, Israel, Kamada was established in 1990.
Market cap
$500.3M
P/E (trailing)
21.68
P/E (forward)
14.53
PEG ratio
0.62
Dividend yield
208.00%
Beta
0.14
52w range
6.50 – 9.35
Return on equity
+8.40%
Profit margin
+11.60%
Revenue growth
+22.70%
Earnings growth
+23.10%
Price history
1Y: 8.67 (+31.0%) · range 6.28–8.85
Cycle position
65/ 100 cycle scoreAPPROACHING EXIT
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 12 · NOT READY · exit proximity 0
Conviction
20/ 100 · maturity 100%
VScore.409
Buildup.2037
EMA entry setup.2512
Fundamentals.1542
Volume profile
POC
8.24
Price vs POC
+5.2%
Overhead supply
0%
Runway
open sky
Value area 7.28–8.46 · 0% of 120d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.033 | Sep 10, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +4.18% | +12.33% | 18/20d |
| 40d | +4.18% | +12.33% | 18/40d |